Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitus

Seko, Yuya; Sumida, Yoshio; Tanaka, Saiyu; Mori, Kumiko; Taketani, Hiroyoshi; Ishiba, Hiroshi; Hara, Tasuku; Okajima, Akira; Umemura, Atsushi; Nishikawa, Taichiro; Yamaguchi, Kanji; Moriguchi, Michihisa; Kanemasa, Kazuyuki; Yasui, Kohichiroh; Imai, Shoichi; Shimada, Kaoru; Itoh, Yoshito

doi:10.1111/hepr.12834

Cited by 85 publications

(91 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Japanese patients with T2DM refractory to dietary intervention with or without antidiabetic drugs, treatment with ipragliflozin (50–100 mg/day) for 12 weeks reduced transaminase activities as well as body weight and body fat . We also recently found that treatment with SGLT2 inhibitors for T2DM patients with biopsy‐proven NAFLD significantly reduced serum transaminase activities as well as body weight and body fat . Thus, we undertook subanalyses in phase II or III trials with canagliflozin from Japan to examine whether canagliflozin can decrease serum transaminase activities in Japanese patients with T2DM.…”

Section: Novel Antidiabetic Drugsmentioning

confidence: 99%

Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus

Sumida

Seko

Yoneda

2017

Hepatology Research

Self Cite

View full text Add to dashboard Cite

Liver-related diseases are the leading causes of death in patients with type 2 diabetes mellitus (T2DM) in Japan. Type 2 diabetes mellitus is closely associated with non-alcoholic fatty liver disease (NAFLD), which is the most prevalent chronic liver disease worldwide. Non-alcoholic steatohepatitis (NASH), a severe form of NAFLD, can lead to hepatocellular carcinoma and hepatic failure. Non-alcoholic steatohepatitis can be called "diabetic hepatopathy". There are no established pharmacotherapies for NAFLD/NASH patients with T2DM. Although metformin is established as the first-line therapy for T2DM, given its relative safety and beneficial effects on glycosylated hemoglobin, weight, and cardiovascular mortality, this agent is not recommended as specific therapy for NASH/NAFLD due to lack of clinical evidence. The effects of pioglitazone on NASH histology with T2DM have been extensively proved, but several concerns exist, such as body weight gain, fluid retention, cancer incidence, and bone fracture. In recent years, novel antidiabetic medications have been approved for T2DM, such as glucagon-like peptide 1 receptor agonists, dipeptidyl peptidase 4 inhibitors, and sodium/glucose cotransporter 2 inhibitors. A key clinical question for hepatologists is what kinds of antidiabetic medications are the most appropriate for the treatment of NAFLD accompanied by T2DM, to prevent progression of hepatic fibrosis resulting in HCC/liver-related mortality without increased risk of cardiovascular events. This review focuses on novel antidiabetic agents and future perspectives on the treatment of NAFLD/NASH with T2DM.

show abstract

Section: Novel Antidiabetic Drugsmentioning

confidence: 99%

Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus

Sumida

Seko

Yoneda

2017

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several SGLT2 inhibitors have shown benefit in murine models of NAFLD, improving steatosis, inflammation, and fibrosis, and studies in humans with T2DM have demonstrated improved ALT and weight loss in patients with type 2 diabetes with ipragliflozin and canagliflozin, as well as reducing fatty liver index score (from 70.1±19.4 to 60.3±25.5, P =.0009) with ipragliflozin . There are no reported human studies assessing changes in liver histology in NAFLD with SGLT2 inhibitors, although one study did demonstrate weight‐independent improvements in serum ALT with ipragliflozin …”

Section: Medications Currently Used In Patients With Nash To Treat Comentioning

confidence: 99%

Review article: new treatments in non‐alcoholic fatty liver disease

Townsend

Newsome

2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackground: Non-alcoholic fatty liver disease is the fastest growing cause of liver disease in the Western world, yet there is no approved pharmacotherapy. While lifestyle modifications remain the mainstay of treatment, only a proportion of individuals are able to make or sustain them, and so more treatment options are required.Aim: To review the potential benefit of drugs used in clinical practice, those entering phase II trials, and compounds being investigated in pre-clinical studies.Methods: A literature search was performed using PubMed to identify relevant studies; linked references were also reviewed.

show abstract

“…All included studies noted a significant improvement in AST and ALT. Some studies also noted that this improvement exceeded or matched that of other diabetes medications such as metformin, pioglitazone, or sitagliptin . Similarly, 5 studies have evaluated the impact of SGLT‐2 inhibitors on hepatic fat and noted significant improvement .…”

Section: Treatment Optionsmentioning

confidence: 97%

Evolution of NAFLD and Its Management

et al. 2019

View full text Add to dashboard Cite

The global prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated to be 25% and continues to rise worldwide in the setting of the obesity epidemic. This increase is especially concerning because NAFLD is often a progressive disease that can be associated with significant complications such as liver cirrhosis, hepatocellular carcinoma, and an increase in liver-related and overall mortality. Because of the devastating complications and comorbidities, NAFLD is a very costly disease for the healthcare system, with estimated annual direct medical costs exceeding $100 billion in the United States alone. Given this progressive course, it is imperative to make the diagnosis in patients with risk factors (metabolic syndrome, weight gain, and insulin resistance/diabetes). Once the diagnosis is made, the focus should shift to treatment and monitoring for the development of associated complications. Given that currently no pharmaceutical intervention is approved for the treatment of NAFLD, focus shifts instead to mitigation of risk factors through avoidance of foods that are rich in red meat, trans fats, refined carbohydrates, and high-fructose corn syrup; are low fiber; and have high energy density. The landmark of treatment, however, continues to be weight loss and improvement of insulin resistance, often through a multimodality approach. The current manuscript reviews the clinical phenotypes of NAFLD, its risk factors, and pathogenesis, as well as treatment options including lifestyle modifications and dietary interventions, medical therapies, endoscopic bariatric interventions, and bariatric surgery. (Nutr Clin Pract. 2020;35:72-84) Keywords fatty liver; insulin resistance; liver cirrhosis; non-alcoholic fatty liver disease; nutrition therapy; weight loss From the

show abstract

Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitus

Abstract: Sodium glucose cotransporter 2 inhibitor can be a novel promising agent for the treatment for NAFLD patients with T2DM. Prospective randomized controlled trials are warranted to confirm this efficacy of SGLT2I on NAFLD with T2DM.

Cited by 85 publications

References 17 publications

Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus

Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus

Review article: new treatments in non‐alcoholic fatty liver disease

Evolution of NAFLD and Its Management

Contact Info

Product

Resources

About